These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 32223357)

  • 21. Serial Cell-Free DNA Sequencing in
    Choudhury NJ; Jun Woo H; Chen M; Shah R; Donoghue M; Berger M; Drilon A
    JCO Precis Oncol; 2024 Jun; 8():e2300721. PubMed ID: 38848521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
    Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
    J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
    Dziadziuszko R; Hung T; Wang K; Choeurng V; Drilon A; Doebele RC; Barlesi F; Wu C; Dennis L; Skoletsky J; Woodhouse R; Li M; Chang CW; Simmons B; Riehl T; Wilson TR
    Mol Oncol; 2022 May; 16(10):2000-2014. PubMed ID: 35338679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRUST-II: a global phase II study of taletrectinib in
    Nagasaka M; Ohe Y; Zhou C; Choi CM; Yang N; Liu G; Felip E; Pérol M; Besse B; Nieva J; Raez L; Pennell NA; Dimou A; Marinis F; Ciardiello F; Seto T; Hu Z; Pan M; Wang W; Li S; Ou SI
    Future Oncol; 2023 Jan; 19(2):123-135. PubMed ID: 36877099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    Fan Y; Drilon A; Chiu CH; Loong HHF; Siena S; Krzakowski M; Dziadziuszko R; Zeuner H; Xue C; Krebs MG
    Clin Lung Cancer; 2024 Mar; 25(2):e81-e86.e4. PubMed ID: 38245456
    [No Abstract]   [Full Text] [Related]  

  • 26. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.
    Facchinetti F; Friboulet L
    Lung Cancer (Auckl); 2019; 10():87-94. PubMed ID: 31572036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving role of entrectinib in treatment of
    Chawla N; Bui NQ; Seetharam M
    Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
    Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
    J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.
    Takumi Y; Arai S; Suzuki C; Fukuda K; Nishiyama A; Takeuchi S; Sato H; Matsumoto K; Sugio K; Yano S
    Cancer Med; 2023 Mar; 12(5):5809-5820. PubMed ID: 36416133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
    Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
    Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
    Peters S; Gadgeel SM; Mok T; Nadal E; Kilickap S; Swalduz A; Cadranel J; Sugawara S; Chiu CH; Yu CJ; Moskovitz M; Tanaka T; Nersesian R; Shagan SM; Maclennan M; Mathisen M; Bhagawati-Prasad V; Diarra C; Assaf ZJ; Archer V; Dziadziuszko R
    Nat Med; 2024 Jul; 30(7):1923-1932. PubMed ID: 38898120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
    Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
    Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
    Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
    Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
    Stanzione B; Del Conte A; Bertoli E; De Carlo E; Revelant A; Spina M; Bearz A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
    Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
    J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ROS1-rearranged Non-small Cell Lung Cancer.
    Giustini NP; Bazhenova L
    Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Approval Summary: Entrectinib for the Treatment of
    Marcus L; Donoghue M; Aungst S; Myers CE; Helms WS; Shen G; Zhao H; Stephens O; Keegan P; Pazdur R
    Clin Cancer Res; 2021 Feb; 27(4):928-932. PubMed ID: 32967940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entrectinib, a new multi-target inhibitor for cancer therapy.
    Jiang Q; Li M; Li H; Chen L
    Biomed Pharmacother; 2022 Jun; 150():112974. PubMed ID: 35447552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
    Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
    Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.